Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Heca Journal of Applied Sciences Malacca Pharmaceutics
Purwanto, Diana Shintawati
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemistry Earth & Planetary Sciences Engineering Health Professions Immunology & microbiology Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Network Pharmacology Insights into Broccoli Microgreens for Prostate Cancer Wijaya, Puspita; Tallei, Trina Ekawati; Tendean, Lydia Estelina Naomi; Fatimawali, Fatimawali; Turalaki, Grace Lendawati Amelia; Purwanto, Diana Shintawati
Heca Journal of Applied Sciences Vol. 3 No. 1 (2025): March 2025
Publisher : Heca Sentra Analitika

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.60084/hjas.v3i1.264

Abstract

Prostate cancer is a leading malignancy in men, ranking fourth globally and fifth in Indonesia (GLOBOCAN 2020). Conventional therapies, though available, are limited by high costs, side effects, and resistance, highlighting the need for accessible alternatives. Broccoli microgreens, rich in bioactive compounds, have shown potential in preventing and treating various cancers. This study hypothesized that bioactive compounds in broccoli microgreens interact with molecular targets involved in prostate cancer progression. To test this hypothesis, we employed a network pharmacology-based in silico approach to systematically explore these interactions and identify potential therapeutic mechanisms. Bioactive compounds in broccoli microgreens were identified using liquid chromatography-mass spectrometry (LC-MS) and analyzed via the PubChem database. The biological activities of these compounds were predicted using PASS Online, focusing on their capacity to modulate TP53 gene expression. Pharmacokinetic and toxicity evaluations were performed using ADMETLab 3.0 and Protox 3.0 to assess their safety and drug-like properties. Target proteins were identified through SwissTargetPrediction and GeneCards, while protein-protein interaction networks were constructed using STRING. The pharmacological network was visualized using Cytoscape to elucidate the molecular mechanisms of action. The analysis identified 528 relevant target proteins, with key roles attributed to SRC and EGFR, both critical in resistance to EGFR tyrosine kinase inhibitors and in regulating processes such as cell proliferation, apoptosis resistance, and metastatic potential. Through network pharmacology, bioactive compounds such as kaempferol and polydatin were identified as potential inhibitors of these targets, demonstrating their ability to modulate pathways essential to prostate cancer progression. In conclusion, broccoli microgreens contain bioactive compounds with potential pharmacological relevance for prostate cancer, particularly through their interaction with SRC and EGFR pathways, warranting further experimental validation.
Targeting Prostate Cancer with Rambutan Peel-Derived Compounds via Network Pharmacology Utami, Wulandari Putri; Tallei, Trina Ekawati; Turalaki, Grace Lendawati Amelia; Tendean, Lydia Estelina Naomi; Kaseke, Martha Marie; Purwanto, Diana Shintawati
Malacca Pharmaceutics Vol. 3 No. 1 (2025): March 2025
Publisher : Heca Sentra Analitika

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.60084/mp.v3i1.262

Abstract

Prostate cancer is a prevalent malignancy in men, originating in the prostate gland and often driven by genetic alterations and hormonal dysregulation. Rambutan (Nephelium lappaceum L.) peel, a byproduct of fruit consumption, has demonstrated potential anticancer activity. This study employed a network pharmacology-based in silico approach to evaluate the therapeutic potential of rambutan peel extract in prostate cancer treatment. Bioactive compounds were identified through database searches, and their biological activities were predicted using PASS Online. Pharmacokinetic and toxicity profiles were assessed using ADMETLab 3.0 and Protox 3.0 to evaluate safety and drug-like properties. Potential target proteins were identified via SwissTargetPrediction and GeneCards, while protein-protein interaction networks were constructed using STRING. The pharmacological networks were visualized using Cytoscape to elucidate molecular mechanisms of action. The analysis identified 28 bioactive compounds in rambutan peel extract, with 11 demonstrating activity against prostate cancer (Pa > 0.5). These compounds were deemed safe based on Lipinski's Rule of Five (Ro5) and categorized within toxicity classes V and VI. Rambutan peel extract was found to target 501 proteins associated with prostate cancer, including key pathways involved in resistance to EGFR tyrosine kinase inhibitors. Network pharmacology analysis highlighted several key target genes, including SRC, GNAI1, PIK3CA, PIK3CD, MAPK1, MAPK3, AKT1, GNAI3, PRKCA, and HSP90AA1. Among these, SRC exhibited the highest centrality score, underscoring its pivotal role in disrupting tumorigenic and metastatic signaling pathways, suppressing cancer cell proliferation, and enhancing therapeutic responses. These findings suggest that rambutan peel extract holds promise as a natural therapeutic agent for prostate cancer, warranting further experimental and clinical validation.
Co-Authors Fatimawali . Martha Marie Kaseke Tendean, Lydia Estelina Naomi TRINA EKAWATI TALLEI Turalaki, Grace Lendawati Amelia Utami, Wulandari Putri Wijaya, Puspita